Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
29.01.24
/
50%
€21.00
Target price
29.01.25
€28.68
Performance (%)
-42.86%
End price
30.01.25
€12.00
Summary
This prediction ended on 30.01.25 with a price of €12.00. The BUY prediction by The_Goldman_Sachs_Gr for Myriad Genetics performed very badly with a performance of -42.86%. The_Goldman_Sachs_Gr has a follow-up prediction for Myriad Genetics where he still thinks Myriad Genetics is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Myriad Genetics | -15.126% | -15.126% | -57.917% |
| iShares Core DAX® | -1.875% | 2.861% | 18.863% |
| iShares Nasdaq 100 | -2.177% | 0.048% | 3.956% |
| iShares Nikkei 225® | -0.867% | 6.987% | 21.062% |
| iShares S&P 500 | -1.253% | 1.248% | 2.246% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
In the thread Trading Myriad Genetics
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten